Strictly Regiocontrolled α-Monosubstitution of Cyclic Carbonyl Compounds with Alkynyl and Alkyl Groups via Pd-Catalyzed Coupling of Cyclic α-Iodoenones with Organozincs
derivatives readily undergo Pd-catalyzed cross coupling with α-iodoenones. Although (s-Bu)2Zn also undergoes Pd-catalyzed cross coupling, only the n-Bu-substituted products were obtained. α-Benzylation and α-homobenzylation can proceed satisfactorily, whereas allylzinc and propargylzinc derivatives undergo only addition to the carbonyl group. Although some promising results have been obtained in α-homoallylation
Disclosed herein are therapeutic agents and/or preventive agents for pain or therapeutic agents and/or preventive agents for a sodium channel associated disease. The present invention provides compounds represented by the following formula (I) or pharmacologically acceptable salts thereof:
Photocycloaddition Reactions of 2-(Alk-3-en-1-ynyl)cyclohex-2-enones
作者:Janne Möbius、Paul Margaretha
DOI:10.1002/hlca.200890240
日期:2008.12
The newly synthesized 2-(alk-3-en-1-ynyl)cyclohex-2-enones 4 undergo photodimerization (chemo- and regio-)selectively at the exocyclic CC bond to give diastereoisomeric mixtures of 1,2-dialkynyl-1,2-dimethylcyclobutanes. On irradiation of 4 in the presence of 2-chloroacrylonitrile, cyclobutane formation occurs again (chemo- and regio-)selectively at the exocyclic CC bond to afford diastereoisomeric
Rhodium-Catalyzed Tandem Addition–Cyclization–Rearrangement of Alkynylhydrazones with Organoboronic Acids
作者:Kyoungmin Choi、Hoyoon Park、Chulbom Lee
DOI:10.1021/jacs.8b05561
日期:2018.8.22
approach allows alkyne-tethered hydrazones and organoboronic acids to undergo a cascade of addition-cyclization-rearrangement reactions to provide cycloalkene products. The process is initiated by the rhodium-catalyzed addition-cyclization and completed with the allylic diazene rearrangement. The reaction can also be rendered asymmetric by using chiral diene ligands for the rhodium catalyst, whereby
Disclosed herein are therapeutic agents and/or preventive agents for pain or therapeutic agents and/or preventive agents for a sodium channel associated disease. The present invention provides compounds represented by the following formula (I) or pharmacologically acceptable salts thereof: